Arbutus Biopharma Corporation Email Format

Biotechnology ResearchPennsylvania, United States11-50 Employees

Arbutus Biopharma Corporation is a clinical-stage biotechnology company focused on infectious disease, headquartered in Warminster, Pennsylvania, with a workforce of 11 to 50 employees. It trades on the Nasdaq under the ticker ABUS. The company is developing two lead programs for chronic hepatitis B virus: imdusiran (AB-729), a GalNAc-conjugated RNA interference therapeutic intended for subcutaneous delivery, and AB-101, a proprietary oral PD-L1 inhibitor. In June 2025, Arbutus launched a Scientific Advisory Board comprising leaders in chronic hepatitis B treatment with extensive experience in late-stage clinical trials, and in March 2026 announced a global settlement with Moderna, Inc. that could result in payments of up to $2.5 billion. The company maintains a website at arbutusbio.com and has reported revenue in the range of $10 million to $25 million.

Sign up for free to view info

Company overview Employee directory